Based on our findings demonstrating the importance of the ASH1L SET domain in MLL leukemia (Fig. 1), we evaluated the effect of the ASH1L inhibitors in a panel of leukemia cells with MLL1 translocations. The gene discussed is KMT2A; the disease is leukemia.